Fighting MDR-TB with Bedaquiline

9 million* new cases of TB worldwide

480,000* cases of multidrug-resistant tuberculosis (MDR-TB) every year

210,000 deaths from MDR-TB in just 2013*

Current MDR-TB treatment is

- Lengthy
- Costly
- Has severe side effects

Bedaquiline, the first new drug to treat TB in more than 40 years, brings new hope to patients fighting MDR-TB with little to no other treatment options.

The bedaquiline donation program is an innovative public-private partnership between USAID and Janssen Therapeutics of Johnson & Johnson. The donation of bedaquiline, combined with technical support provided by USAID, will enable patients in nearly 100 countries to access this life-saving medication and fight MDR-TB.

2013: Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.